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Introduction
Oesophageal carcinoma is the seventh most common cause of cancer-related death in the Western world and the incidence is increasing [1] . The major challenge in the treatment of oesophageal carcinoma is to reduce the risk of local recurrence. Following surgical resection, local tumour recurrence occurs in approximately 50% of all patients. Most of these recurrences occur within the first year after surgery, and the prognosis for these patients is dismal [2] . For patients treated with curatively intended radiotherapy or radiochemotherapy (including radiation doses at the limit of normal-tissue tolerance), approximately 80% relapse at the primary site [3] . Despite new treatment modalities, survival remains poor for patients with oesophageal carcinoma, and treatment-related toxicity can be devastating. Consequently, selecting appropriate patients for the different treatment modalities is crucial, as is identifying predictive factors for response to therapy.
The epidermal growth factor (EGF) receptor (EGFR) family members, EGFR (also called ERBB1), ERBB2 (also called HER2 or Neu), ERBB3, and ERBB4 and their ligands are important for the development and progression of various malignancies [4] . In oesophageal carcinoma, EGFR has been reported to be commonly overexpressed [5] , and the overexpression seems to be independent of mutations in TP53, RAS, or other investigated oncogenes. The signal cascade system of EGFR is involved in oesophageal tumour growth, and EGFR-targeted therapies have been shown to be capable of suppressing this growth [6] .
Leucine-rich and immunoglobulin-like domains (LRIG) 1, 2, and 3 are integral membrane proteins containing an extracellular or luminal region consisting of a leucine-rich repeats domain and three immunoglobulin-like domains, a transmembrane domain, and a cytosolic tail [7] [8] [9] [10] . LRIG1 has been postulated to be a tumour suppressor [11] and shown to counteract the signalling of EGFR [12, 13] , MET [14] , and RET [15] receptors. LRIG1 participates in an EGF-driven negative feedback loop involving receptor ubiquitination and degradation leading to the suppression of EGFR receptor signalling. Less is known about the function of the other two human LRIG paralogs, LRIG2 and LRIG3. The location of the LRIG1, 2, and 3 genes at chromosomes 3p14, 1p13, and 12q13, respectively, also indicates interesting functions in different tumour forms [7] [8] [9] . LRIG1 is expressed in most or all tissues [8] and has also been suggested to be of prognostic significance in several malignancies [11] . For example, LRIG1 expression is down-regulated in renal cell carcinoma [16] , and high LRIG1 expression is associated with long survival in squamous cell carcinoma of the skin and cervix [17, 18] .
LRIG2 expression, on the other hand, has been associated with short survival in oligodendroglioma [19] and squamous cell carcinoma of the uterine cervix [20] . In the present study we investigated the clinical implications of EGFR and LRIG1-3 expression in oesophageal carcinoma with the aim of investigating their clinical prognostic effect.
Furthermore, the importance of the expression levels of the EGFR and LRIG family members for the sensitivity of oesophageal carcinoma cell lines for standard chemotherapeutic agents was analysed.
Patients and Methods

Patients
Between 1990 and 2000, 126 patients were recorded as having received treatment for oesophageal carcinoma at the Department of Oncology, Uppsala University Hospital, Sweden. Treatment strategies for these patients were preoperative chemotherapy and radiation treatment followed by surgery, curatively intended radiation treatment or palliative treatment The study was reviewed and approved by the research ethics committee, Uppsala University, Uppsala, Sweden.
Immunohistochemistry
The immunohistochemical staining procedures have previously been described for EGFR [21] , LRIG1 [8] , LRIG2 [22] , and LRIG3 [23] . Briefly, 4 µm-thick tissue sections were labelled with the following primary antibodies at the indicated concentrations: anti-EGFR 1005 (2 μg/ml, Santa Cruz Biotechnology, Santa Cruz, CA, USA,), anti-LRIG1 (0.5 μg/ml, AgriSera, Vännäs, Sweden), anti-LRIG2 (1 μg/ml), and anti-LRIG3 (2.2 μg/ml).
Immunodetection was achieved by using horseradish peroxidase-conjugated secondary antibodies and the substrate diaminobenzidine. The slides were counterstained with haematoxylin and mounted in glycerol-gelatin.
Scoring of immunostainings
The evaluation of the immunostaining was blinded with respect to the clinical parameters of the patients and performed by two independent observers. Immunostainings were scored as previously described [24] . The subcellular localisation of the stainings was evaluated and found to be predominantly cyoplasmic in all stainings. The different tumour stainings were compared to each other and used as internal controls.
Cell culturing
The human oesophageal squamous cell carcinoma cell lines KYSE30, KYSE70, KYSE140, KYSE150, KYSE180, KYSE410, KYSE450, KYSE510, and KYSE520 (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Braunschweig, Germany) were cultivated in RPMI 1640 medium, supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 50 U/ml penicillin, and 100 µg/ml streptomycin (Sigma-Aldrich Sweden AB, Stockholm, Sweden) in 37°C humidified air with 5% CO 2 . Cells were sub-cultivated twice weekly and harvested in log-phase for experimental use.
Cytotoxicity assay
The fluorometric microculture cytotoxicity assay (FMCA) [25] Prism (GraphPad Software Inc., La Jolla, CA, USA). All concentrations were tested in duplicates, and the experiments were repeated at least twice.
Quantitative real-time RT-PCR
RNA was prepared and analysed by quantitative real-time RT-PCR, as previously described for EGFR [16] , LRIG1 and 18S rRNA [26] , LRIG2 [7] and LRIG3 [27] . Triplicate samples of 20 ng of total RNA from exponentially growing cells were analysed, and relative RNA quantification was performed by comparing the threshold cycle values for the samples with standard curves generated with plasmid DNA containing cloned cDNA-fragments of respective genes. The mRNA levels were normalised to the 18S rRNA levels in respective samples.
Statistics
The survival functions were estimated with the Kaplan-Meier product limit estimator method and the median survival time estimated with linear interpolation of the survival function. The univariate statistical comparisons of the data were made using log-rank tests. Correlations to sensitivity for chemotherapeutic agents were analysed using Spearman rank order correlations. Kruskal-Wallis correlation test was used to determine statistical significance.
Throughout this study, a 5% significance level was used in the statistical tests.
Results
Immunohistochemistry and clinical data
In the present study, a total of 80 patients were included. The most frequent histology was squamous cell carcinoma; further descriptive statistics are shown in Table 1 . Protein expression analyses using an immunohistochemical method demonstrated widespread but variable expression levels of EGFR and LRIG1-3 in the tumours. In all cases a predominant cytoplasmic staining was observed (Fig 1A-D) . Correlation analysis between immunohistochemically investigated proteins showed a significant correlation between EGFR and LRIG3 expression (p=0.006, R=0.37). The other investigated parameters were not significantly correlated to each other or to clinical parameters. Survival analysis showed that the total score, based on low or high expression of fraction and intensity, was not significantly correlated to survival for LRIG1 (p=0.65) nor LRIG3 (p=0.75). A trend towards decreased survival was found for low expression of EGFR (p=0.09) (Fig 2) and high expression of LRIG2 (p=0.18) (Fig 3) , although not statistically significant. Multivariate analyses of all investigated parameters in correlation to clinical data are shown in Table 1 .
Cytotoxicity assays and RT-PCR
The possible influence of EGFR family and LRIG proteins on sensitivity to conventional chemotherapeutic agents in a panel of oesophageal carcinoma cell lines was investigated. The RNA expression levels of ERBB1 (EGFR) and LRIG1-3 were evaluated by quantitative real-time RT-PCR and the sensitivity to a panel of cytotoxic drugs was determined by the FMCA method (Tables III and IV) . Statistically significant correlations were found between expression of LRIG1 and sensitivity to cisplatin (r = -0.74), docetaxel (r = -0.69), and vinorelbine (r = -0.82) (Table V, Figure 3a -c).
Discussion
LRIG proteins have been proposed to be of importance in the pathogenesis of various tumours, [11, 23] and LRIG1 has been shown to inhibit growth factor signalling from the oncogenic receptor tyrosine kinases EGFR, MET, and RET [12] [13] [14] 28] . We evaluated for the first time the expression of LRIG proteins in oesophageal cancer. Our results show that there is a positive correlation between EGFR expression and LRIG3 expression. This is in contrast with data from Guo et al. [29] who found that the expression of LRIG1-3 in the human pituitary adenoma cell line HP75 cell line was lower, but the expression of EGFR was higher, consistent with the notion of LRIG1-3 being tumour suppressor genes and that LRIGs decrease the expression of EGFR. Survival analysis showed no significant correlation to survival for LRIG1 (p=0.65) or LRIG3 (p=0.75). A trend towards decreased survival was found for low expression of EGFR (p=0.09) (Fig 2) and high expression of LRIG2 (p=0.18) (Fig 3) , although not statistically significant. This mirrors to some extent the situation in cervical squamous cell carcinoma, where high expression of LRIG2 is associated with poor survival [20] , whereas LRIG1 is associated with better survival [18] , indicating that the functions of LRIG1 and LRIG2 may be different.
Furthermore, cytoplasmic LRIG2 expression was found to be an independent prognostic factor associated with poor oligodendroglioma patient survival [19] .
The incidence of EGFR-expressing oesophageal tumours remains controversial, with frequencies from as many as 99% to as few as 29% reported [30] . Wang et al. reported that patients with oesophageal and oesophagogastric junction adenocarcinomas had shorter survival if EGFR expression was present, compared to those who were negative for EGFR [31] . Furthermore, EGFR overexpression was significantly related to vascular invasion in squamous cell carcinoma patients. However, others have found the prognostic value of EGFR to be limited [32, 33] , and the function of EGFR protein expression as a prognostic factor is thus unclear. However, the EGFR pathway has been implicated in the pathophysiology of oesophageal cancer and EGFR inhibitors are being explored in these patients [34] . The present study supports the notion that EGFR protein expression has limited prognostic implications in oesophageal carcinoma. Instead, other mechanisms may be involved in determining prognosis as indicated by Kaneko et al. who found that a silent mutation, comprised of a single nucleotide polymorphism (SNP) at codon 787 of exon 20 of the EGFR gene, was a negative prognostic factor in patients with esophageal squamous cell carcinoma [33] . Furthermore, our analysis demonstrated no correlation between EGFR expression and tumour stage, as opposed to data by Wang et al. demonstrating that EGFR expression in oesophageal adenocarcinomas was correlated with advanced pathologic tumour classification and lymph node metastasis. In the same study EGFR expression was also correlated with poor disease-free and overall survival, but that correlation was not independent of T classification [35] .
The importance of the expression levels of EGFR and LRIG family members for the sensitivity of oesophageal carcinoma cell lines to conventional chemotherapeutic agents was investigated. Statistically significant correlations were found between expression levels of LRIG1 and sensitivity to cisplatin, docetaxel, and vinorelbine. The correlation between LRIG1 levels and sensitivity to cisplatin is consistent with reported results on malignant glioma cells, where ectopic expression of LRIG1 in U87MG EGFRvIII cells resulted in increased sensitivity to cisplatin and temozolomide [36] . Also for targeted therapies, a possible link between LRIG1 activity and the sensitivity to EGFR tyrosine kinase inhibitors may be inferred, firstly because LRIG1 negatively regulates EGFR itself, and secondly because LRIG1 negatively regulates MET and ERBB3, which have been shown to mediate resistance to EGFR inhibition [37] . Furthermore, there is evidence that EGFR signalling may confer resistance also to conventional chemotherapy. Thus, it seems possible that the effects of LRIG1 on the cellular sensitivity to cisplatin, docetaxel, and vinorelbine reported here and elsewhere is mediated, at least in part, by its suppression of EGFR signalling.
In summary, we show in the present study that EGFR and the LRIG proteins are widely expressed in oesophageal carcinoma, and may be functionally involved and of predictive but limited prognostic significance in oesophageal carcinoma. Further and larger studies are needed, however, to fully elucidate the prognostic and predictive value of EGFR and LRIG proteins in oesophageal carcinoma, and to reveal the functional relationships between these proteins and the aetiology of the disease and its response to therapy.
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